Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Analytical Method Development: SOP for GC-MS Method for Residual Solvents – V 2.0

Posted on By

Analytical Method Development: SOP for GC-MS Method for Residual Solvents – V 2.0

Standard Operating Procedure for GC-MS Method Development for Residual Solvents


Department Analytical Method Development
SOP No. SOP/AMD/167/2025
Supersedes SOP/AMD/167/2022
Page No. Page 1 of 14
Issue Date 19/05/2025
Effective Date 20/05/2025
Review Date 19/05/2026

1. Purpose

This SOP outlines the procedure for developing, optimizing, and validating Gas Chromatography-Mass Spectrometry (GC-MS) methods for identification and quantification of residual solvents in drug substances and drug products, in

compliance with ICH Q3C and regulatory expectations.

2. Scope

This procedure applies to the Analytical Method Development (AMD) laboratory for pharmaceutical API and formulation batches containing residual solvents categorized under Class 1, 2, and 3 per ICH Q3C guidelines.

3. Responsibilities

  • Analytical Scientist: Responsible for method development, optimization, and validation of GC-MS methods for residual solvent analysis.
  • QA Officer: Ensures regulatory compliance by reviewing protocols, data, and final reports.
  • GC-MS Analyst: Sets instrument parameters, verifies calibration, and ensures data integrity.
  • Head – AMD: Reviews and approves method validation and standard operating procedures.
See also  Analytical Method Development: Selection of HPLC Column and Mobile Phase - V 2.0

4. Accountability

The Head of Analytical Method Development is accountable for ensuring validated GC-MS methods for residual solvents are available and compliant with current regulatory standards.

5. Procedure

5.1 Selection of Target Solvents

  1. Identify solvents used in the synthesis or formulation from production records.
  2. Classify solvents as per ICH Q3C:
    • Class 1: Benzene, Carbon tetrachloride, etc. (to be avoided)
    • Class 2: Methanol, Acetonitrile, Toluene, etc. (to be limited)
    • Class 3: Ethanol, Acetone, etc. (low toxic potential)
  3. Establish permissible limits based on daily intake thresholds.

5.2 Sample Preparation

  1. Weigh 500–1000 mg of sample into a headspace vial.
  2. Add 5 mL of suitable diluent (e.g., DMSO, water, or DMF depending on solubility).
  3. Seal vials using crimp-top and magnetic cap; vortex to mix.
  4. Include internal standard (e.g., 1-butanol or acetone-d6).

5.3 GC-MS Method Setup

  1. Use a capillary column such as DB-624 (30 m x 0.32 mm x 1.8 µm) for volatile organic compounds.
  2. GC Parameters:
    • Carrier gas: Helium at 1.0 mL/min
    • Injection mode: Split or splitless depending on detection limit
    • Injector temp: 200°C
    • Oven program: 40°C (hold 5 min) → 240°C at 10°C/min
  3. MS Parameters:
    • Ionization: Electron Impact (EI)
    • Scan range: m/z 30–300
    • Source temp: 230°C
    • Quadrupole temp: 150°C
  4. Record details in Annexure-1: GC-MS Method Log.
See also  Analytical Method Development: Sink Condition Determination SOP - V 2.0

5.4 Calibration and Standard Curve

  1. Prepare calibration standards at 0.5x, 1.0x, and 1.5x of ICH limits.
  2. Include internal standard in all calibration solutions.
  3. Construct standard curve using peak area ratio (Analyte/IS) vs concentration.
  4. R² ≥ 0.995 is required for acceptance.

5.5 Method Validation

  1. Validate method parameters per ICH Q2(R2):
    • Specificity
    • Linearity (R² ≥ 0.995)
    • Accuracy (recovery 90%–110%)
    • Precision (RSD ≤ 5%)
    • LOD and LOQ determination
  2. Document results in Annexure-2: Validation Report.

5.6 Sample Analysis

  1. Analyze sample in triplicate and report mean content for each solvent.
  2. Check for co-elution or interference using spiked placebo and blank runs.
  3. Calculate residual solvent levels using internal standard calibration.
  4. Enter results in Annexure-3: Sample Result Log.

6. Abbreviations

  • GC-MS: Gas Chromatography – Mass Spectrometry
  • LOD: Limit of Detection
  • LOQ: Limit of Quantification
  • ICH: International Council for Harmonisation
  • IS: Internal Standard
  • SOP: Standard Operating Procedure
See also  Analytical Method Development: Preparation of Calibration Curve in UV - V 2.0

7. Documents

  1. GC-MS Method Log – Annexure-1
  2. Validation Report – Annexure-2
  3. Sample Result Log – Annexure-3

8. References

  • ICH Q3C(R8) – Impurities: Guideline for Residual Solvents
  • ICH Q2(R2) – Validation of Analytical Procedures
  • USP <467> – Residual Solvents
  • FDA Guidance for Industry – Residual Solvents in Drug Products

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: GC-MS Method Log

Analyte Retention Time (min) m/z IS Method ID Analyst
Methanol 3.5 32 1-butanol GCMS/RS/001 Rajesh Kumar

Annexure-2: Validation Report

Parameter Result Acceptance Criteria Status
Linearity R² = 0.9975 ≥ 0.995 Pass
Recovery 96.2%–102.3% 90%–110% Pass

Annexure-3: Sample Result Log

Sample ID Solvent Amount (ppm) Limit Status
API/2025/054 Acetonitrile 38 ≤ 410 Complies

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Added internal standard use and detailed validation section Annual SOP Review
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: Biosimilars: SOP for Steam-In-Place (SIP) Procedures – V 2.0
Next Post: Gel Manufacturing: SOP for Conducting Long-Term Stability Studies on Gels – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2026 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version